Additive Effect of Qidan Dihuang Grain, a Traditional Chinese Medicine, and Angiotensin Receptor Blockers on Albuminuria Levels in Patients with Diabetic Nephropathy: A Randomized, Parallel-Controlled Trial

Evidence-based Complementary and Alternative Medicine

Volumn 2016, Issue , 2016, Pages

  Xiang, Lei ^a   Jiang, Pingping ^a   Zhou, Lin ^a   Sun, Xiaomin ^a   Bi, Jianlu ^b   Cui, Lijuan ^c   Nie, Xiaoli ^a   Luo, Ren ^a   Zhao, Xiaoshan ^a   Liu, Yanyan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangdong Province Institute of Traditional Chinese Medicine   (China)

^c Guangdong   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; CHINESE DRUG; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; QIDAN DIHUANG GRAIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINESE MEDICINE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; FEMALE; GLYCYRRHIZA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REHMANNIA; SALVIA MILTIORRHIZA; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 84976370581     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2016/1064924     Document Type: Article

References (23)

1. K. R. Tuttle, G. L. Bakris, R.W. Bilous et al., "Diabetic kidney disease: A report from an ADA Consensus Conference, " American Journal of Kidney Diseases, vol. 64, no. 4, pp. 510-533, 2014.
2. G. L. Bakris and M. Molitch, "Microalbuminuria as a risk predictor in diabetes: The continuing saga, " Diabetes Care, vol. 37, no. 3, pp. 867-875, 2014.
3. Z. Cao and M. E. Cooper, "Pathogenesis of diabetic nephropathy, " Journal of Diabetes Investigation, vol. 2, no. 4, pp. 243-247, 2011.
4. H.-H. Parving, B. M. Brenner, J. J. V. McMurray et al., "Cardiorenal end points in a trial of aliskiren for type 2 diabetes, "The NewEngland Journal ofMedicine, vol. 367, no. 23, pp. 2204-2213, 2012.
5. R. Bilous, N. Chaturvedi, A. K. Sjølie et al., "Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials, " Annals of InternalMedicine, vol. 151, no. 1, pp. 11-20, 2009.
6. M. Mauer, B. Zinman, R. Gardiner et al., "Renal and retinal effects of enalapril and losartan in type 1 diabetes, " The New England Journal of Medicine, vol. 361, no. 1, pp. 40-51, 2009.
7. The Microvascular Complications Group of Diabetes Association of the ChineseMedical Association, "The expert consensus of diabetic kidney disease prevention and control, " Chinese Journal of Diabetes Mellitus, vol. 6, no. 11, pp. 792-801, 2014.
8. G. D. Sun, C. Y. Li, W. P. Cui et al., "Review of herbal traditional chinese medicine for the treatment of diabetic nephropathy, " Journal of Diabetes Research, vol. 2016, Article ID 5749857, 18 pages, 2016.
9. X. Liu, L. Liu, P. Chen et al., "Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy-A systematic review based on a subgroup analysis, " Journal of Ethnopharmacology, vol. 151, no. 2, pp. 810-819, 2014.
10. Y. Xiao, Y. Liu, K. Yu et al., "The effect of Chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: A systematic review and meta-Analysis, " Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 937549, 11 pages, 2013.
11. Y. Y. Zheng, Guidelines for Clinical Research of ChineseMedicine (New Drug), ChineseMedicine and Science Publication House, Beijing, China, 2002.
12. C. Mora-Ferńandez, V. Doḿinguez-Pimentel, M. M. de Fuentes, J. L. Ǵorriz, A. Martínez-Castelao, and J. F. Navarro-Gonźalez, "Diabetic kidney disease: from physiology to therapeutics, " The Journal of Physiology, vol. 592, no. 18, pp. 3997-4012, 2014.
13. D. de Zeeuw, "Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?" Kidney International. Supplement, no. 92, pp. S2-6, 2004.
14. D. de Zeeuw, G. Remuzzi, H.-H. Parving et al., "Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy, " Circulation, vol. 110, no. 8, pp. 921-927, 2004.
15. F. A. Holtkamp, D. de Zeeuw, P. A. deGraeff et al., "Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials, " European Heart Journal, vol. 32, no. 12, pp. 1493-1499, 2011.
16. T. Ninomiya, V. Perkovic, B. E. de Galan et al., "Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes, " Journal of the American Society of Nephrology, vol. 20, no. 8, pp. 1813-1821, 2009.
17. R. E. Schmieder, R. Schutte, H. Schumacher et al., "Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: An analysis of the ONTARGET and TRANSCEND studies, " Diabetologia, vol. 57, no. 10, pp. 2019-2029, 2014.
18. G. L. Bakris, "Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus, " Mayo Clinic Proceedings, vol. 86, no. 5, pp. 444-456, 2011.
19. H. Yamout, I. Lazich, andG. L. Bakris, "Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease, " Advances in Chronic Kidney Disease, vol. 21, no. 3, pp. 281-286, 2014.
20. M. Li, W. Wang, J. Xue, Y. Gu, and S. Lin, "Meta-Analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy, " Journal of Ethnopharmacology, vol. 133, no. 2, pp. 412-419, 2011.
21. S.-H. Lee, Y.-S. Kim, S.-J. Lee, and B.-C. Lee, "The protective effect of Salvia miltiorrhiza in an animal model of early experimentally induced diabetic nephropathy, " Journal of Ethnopharmacology, vol. 137, no. 3, pp. 1409-1414, 2011.
22. Z. Dong and C. X. Chen, "Effect of catalpol on diabetic nephropathy in rats, " Phytomedicine, vol. 20, no. 11, pp. 1023-1029, 2013.
23. J. Li, Y. S. Lee, J.-S. Choi et al., "Roasted licorice extracts dampen high glucose-inducedmesangial hyperplasia and matrix deposition through blocking Akt activation and TGF-signaling, " Phytomedicine, vol. 17, no. 10, pp. 800-810, 2010.